XML 50 R36.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2014
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 336,794 $ 261,016 $ 261,004  
Strategic alliance - MABA program        
Revenue Recognition and Collaborative Arrangements        
Revenue recognized upon termination of contract 10,000      
Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 326,794 261,016 261,004  
Revenue from collaborative arrangements with a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 10,000 0 0  
GSK        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 336,794 261,016 261,004  
Milestone fees paid $ 220,000 220,000    
GSK | Long-Acting Beta2 Agonist (LABA) Collaboration        
Revenue Recognition and Collaborative Arrangements        
Milestone fees paid       $ 220,000
Percentage of economic interest in any future payments made under the agreements 15.00%      
GSK | Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party $ 340,617 274,839 274,827  
Less: amortization of capitalized fees paid to a related party (13,823) (13,823) (13,823)  
Total net revenue 326,794 261,016 261,004  
GSK | RELVAR/BREO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party $ 221,536 189,424 220,162  
GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration        
Revenue Recognition and Collaborative Arrangements        
Royalty rate for first level of annual global net sales (as a percent) 15.00%      
Annual global sales level used to determine royalty rate $ 3,000,000      
Royalty rate for sales above first level of annual global net sales (as a percent) 5.00%      
GSK | ANORO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party $ 45,992 42,625 41,286  
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum        
Revenue Recognition and Collaborative Arrangements        
Royalty rate for combination products (as a percent) 6.50%      
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum        
Revenue Recognition and Collaborative Arrangements        
Royalty rate for combination products (as a percent) 10.00%      
GSK | TRELEGY        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party $ 73,089 42,790 13,379  
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum        
Revenue Recognition and Collaborative Arrangements        
Royalty rate for combination products (as a percent) 6.50%      
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum        
Revenue Recognition and Collaborative Arrangements        
Royalty rate for combination products (as a percent) 10.00%      
GSK | Revenue from collaborative arrangements with a related party | Strategic alliance - MABA program        
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 10,000 $ 0 $ 0